Barrow, William WPROFESSOR
Sitlington Chair in Infectious Diseases
Specialty: Emerging Infectious Diseases
B.S. , Midwestern State University, Wichita Falls, Texas
M.S., University of Houston, Houston, Texas
Ph.D., Colorado State University, Fort Collins, Colorado
Department: Veterinary Pathobiology
250 McElroy Hall
Stillwater, OK 74078
Office: (405) 744-1842
Fax: (405) 744-3738
- Member of the Oklahoma State University chapter of the National Academy of Inventors; inducted February 20, 2013.
- Member of the Biological & Emerging Infections Resources Repository Program (BEI Resources/NIAID) Scientific Working Group (SWG), 2010-2012.
- OSU Regents Distinguished Research Award, 2007.
- AcademicKeys Who's Who in Veterinary Medicine Higher Education, inclusion March 2006.
- Honorary member of Phi Zeta Honor Society of Veterinary Medicine, 2004.
- AIDS and Related Illnesses Collaboration Award (AIDS-FIRCA): international research collaboration award from the Fogarty International Center, NIH; conducted in the Unité de la Tuberculose et des Mycobactéries, L'Institut Pasteur de la Guadeloupe, French West Indies, 1995-99.
- Fogarty Senior International Fellowship for research sabbatical at the L'Institut Pasteur de la Guadeloupe, Pointe-à-Pitre, French West Indies: research conducted in the Unité de la Tuberculose et des Mycobactéries, March-May, 1994.
- Fogarty Senior International Fellowship for research sabbatical at the L'Institut Pasteur, Paris, France, 1992 - 1993: research conducted in the Unité de la Tuberculose et des Mycobactéries.
- Distinguished Alumnus for the Year, 1993, Midwestern State University, Wichita Falls, Texas.
- Heiser Postdoctoral Fellowship, August-1978 to July-1980, National Jewish Hospital and Research Center, Denver, Colorado: fellowship was funded by the Heiser Fellowship Program for Research in Leprosy.
- Member, NIH AIDS and Related Research Study Section [AARR-3], Centers for Scientific Review, 2001-2004. In 2003, the name was changed to AIDS Discovery and Development of Therapeutics (ADDT) Study Section.
- Member of American Society for Microbiology, 1973 - present.
- Member of the Association des Anciens Eleves de L'Institut Pasteur, 1993 - present.
Fields of Interest:
Emerging infectious diseases, antimicrobial drug resistance, drug development, drug delivery.
Current Research Focus:
Infectious diseases (current and emerging), antimicrobial drug resistance, drug screening, drug development, drug delivery, high-throughput screening procedures, biodefense research programs, including NIH/NIAID grants and contracts.
Current Extramural Research Support
NIH/NIAID/DMID. Grant R01 AI090685-01. “Broad-spectrum Antifolates for Treatment of Drug Resistant Bacillus anthracis”. Response to RFA AI-09-026, “Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (R01). PI: W.W. Barrow. July 2, 2010 – June 30, 2015.
- The research on this National Institutes of Health grant was highlighted in this video televised during OSU athletic events:
International Innovation, published by Research Media, is the leading global dissemination resource for the wider scientific, technology and research communities, dedicated to disseminating the latest science, research and technological innovations on a global level. More information and a complimentary subscription offer to the publication can be found at: www.international-innovation-northamerica.com
NIH/NIAID/DMID. Drug-Screening IDIQ Contract HHSN272201100020I “In Vitro Assessment for Antimicrobial Activity - Part A”. June 1, 2011-May 31, 2018. Purpose is to provide NIAID with a broad and flexible range of in vitro assay capabilities for human infectious diseases of human importance caused by infectious agents. The broad scope will allow NIAID to respond to changing priorities as scientific and public health needs shift, including rapid responses to public health emergencies. The scope of work encompasses any type of in vitro assay work needed for infectious disease research, to include routine screening of products and development of new in vitro assays and database management of work.
Nammalwar, B., R.A. Bunce, K. D. Berlin, C. R. Bourne, P.C. Bourne, E.W. Barrow, and W.W. Barrow (2012). Approaches to iodinated derivatives of vanillin and isovanillin. Org. Prep. Proced. Int.: New J. Org. Synth. 44:146-152.
Bourne, C.R., N. Wakeham, K.D. Berlin, R.A. Bunce, B. Nammalwar, W.W. Barrow. (2012). Classifying compound mechanism of action for linking whole cell phenotypes to molecular targets. J. Molec. Recog. 25:216-223.
Nammalwar, B., R.A. Bunce, K.D. Berlin, C.R. Bourne, P.C. Bourne, E.W. Barrow, W.W. Barrow. (2012). Microwave-assisted Heck synthesis of substituted 2,4-diaminopyrimidine-based antibiotics. Org. Prep. Proced. Int. 44:281-287.
Nammalwar, B., R.A. Bunce, K.D. Berlin, C.R. Bourne, P.C. Bourne, E.W. Barrow, W.W. Barrow. (2012). Synthesis and biological activity of substituted 2,4-diaminopyrimidines that inhibit Bacillus anthracis.Eur. J. Med. Chem. 54:387-39.
Barrow, E.W., P.A. Clinkenbeard, R.A. Duncan-Decocq, R.F. Perteet, K.D. Hill, P.C. Bourne, M.W. Valderas, C.R. Bourne, N.L. Clarkson, K.D. Clinkenbeard, W.W. Barrow. (2012). High-throughput screening of diversity collection using biodefense Category A and B priority pathogens. J. Biomol. Screen. 17:946-956.
Nammalwar, B., C.R. Bourne, R.A. Bunce,N. Wakeham, P.C. Bourne, K. Ramnarayan,S. Mylvaganam, K.D. Berlin, E.W. Barrow and W.W. Barrow. (2012). Inhibition of Bacterial Dihydrofolate Reductase by 6-Alkyl-2,4-diamino-pyrimidines. Chem. Med. Chem. 7:1974-1982
Bourne, C.R., N. Wakeham, B. Nammalwar, V. Tseitin, P.C. Bourne, E.W. Barrow, S. Mylvaganam, K. Ramnarayan, R.A. Bunce, K.D. Berlin, W.W. Barrow. (2013). Structure-activity relationship for enantiomers of potent inhibitors of B. anthracis, dihydrofolate reductase. Biochim. Biophys. Acta. 1834:46-52. Online currently at : http://dx.doi.org/10.1016/j.bbapap.2012.09.001
Nammalwar, B., R.A. Bunce,K.D. Berlin, C.R. Bourne, P.C. Bourne, E.W. Barrow and W.W. Barrow. (2013). Comparative study of the Frech catalyst with two conventional catalysts in the Heck synthesis of 2,4-diaminopyrimidine-based antibiotics. Organic Preparations and Procedures International: The New Journal for Organic Synthesis. 45:66-71.
Barrow, W.W. (2013). Safeguarding Against Inhalation Anthrax. International Innovation. North America-November 2013 issue "High Hopes for Health": 117-119; Research Roundtable, 91-93. http://www.research-europe.com/index.php/digital_magazine/international-innovation-healthcare
Bourne, C.R., N. Wakeham, N. Webb, B. Nammalwar, R.A. Bunce, K.D. Berlin, W.W. Barrow. (2014). The structure and competitive substrate inhibition of dihydrofolate reductase from Enterococcus faecalis reveal restrictions to cofactor docking. Biochemistry. 53:1228-1238. The DOI assigned to this article is 10.1021/bi401104t. http://pubs.acs.org/doi/abs/10.1021/bi401104t
Nammalwar, B., N.P. Muddala, C.R. Bourne, M. Henry, P.C. Bourne, R.A. Bunce, E. W. Barrow, K.D. Berlin, W.W. Barrow (2014). Synthesis and Biological Evaluation of 2,4-Diaminopyrimidine-Based Antifolate Drugs against Bacillus Anthracis. Molecules. 19:3231-3246. The DOI assigned to this article is doi:10.3390/molecules1903323. http://www.google.com/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&ved=0CCcQFjAA&url=http%3A%2F%2Fwww.mdpi.com%2F1420-3049%2F19%2F3%2F3231%2Fpdf&ei=OAgqU4f2NcidqgHkoYGICA&usg=AFQjCNFWIBN-kXnwWXBdTPL2SoGeVMxL9Q&bvm=bv.62922401,d.aWM
U.S. Patent No. 6,229,001. Issued Date May 8, 2001. For: “Mycobacterium Fol A Gene That Encodes For The Enzyme Dihydrofolate Reductase”. Inventors: W.W. Barrow, S. Zwyno-Van Ginkel, T.P. Dooley, W.J. Suling. Assignee: Southern Research Institute, Birmingham, AL.
U.S. Patent No. 6,264,991. Issued Date July 24, 2001. For: “Compositions and Methods for Treating Intracellular Infections”. Inventors: W.W. Barrow, E.L. Barrow, D.C. Quenelle, G.A. Winchester, J.K. Staas. Assignee: Southern Research Institute, Birmingham, AL.
U.S. Patent No. 6,559,295. Issued Date May 6, 2003. For:”Mycobacterial FolA Gene That Encodes For The Enzyme Dihydrofolate Reductase”. Inventors: W.W. Barrow, S. Zwyno-Van Ginkel, T.P. Dooley, W.J. Suling. Assignee: Southern Research Institute, Birmingham, AL.
U.S. Patent No. 8,268,825. Issued Date September 18, 2012. For: “Method for the treatment of anthrax infections”. Inventors: Jürg Dreier, Esther Barrow, William Barrow. Assignee: The Board of Regents for Oklahoma State University.
WIPO|PCT International Patent Application No. WO 2013/138787 A1. Published September 19, 2013. For "Highly 6-substituted-2,4-diaminopyrimidines as Inhibitors of Anthrax". Inventors: William Barrow, Christina Bourne, Richard Bunce, Kenneth D. Berlin, Baskar Nammalwar, Kalyanaraman Ramnarayan. Applicant: The Board of Regents for Oklahoma State University.